Rhumbline Advisers Has $383,000 Stock Holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Rhumbline Advisers grew its position in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 8.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 164,508 shares of the company’s stock after purchasing an additional 12,473 shares during the quarter. Rhumbline Advisers owned approximately 0.08% of Allogene Therapeutics worth $383,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in ALLO. Price T Rowe Associates Inc. MD lifted its stake in shares of Allogene Therapeutics by 76.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 4,177,619 shares of the company’s stock worth $18,675,000 after acquiring an additional 1,806,147 shares during the period. Affinity Asset Advisors LLC acquired a new position in shares of Allogene Therapeutics in the fourth quarter worth approximately $1,284,000. Susquehanna Fundamental Investments LLC acquired a new position in shares of Allogene Therapeutics in the first quarter worth approximately $1,280,000. Caxton Associates LP lifted its stake in shares of Allogene Therapeutics by 61.4% in the fourth quarter. Caxton Associates LP now owns 775,093 shares of the company’s stock worth $2,488,000 after acquiring an additional 294,989 shares during the period. Finally, Superstring Capital Management LP acquired a new position in shares of Allogene Therapeutics in the fourth quarter worth approximately $713,000. 83.63% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts recently commented on ALLO shares. HC Wainwright reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Allogene Therapeutics in a research note on Thursday, August 15th. Oppenheimer began coverage on Allogene Therapeutics in a research note on Thursday, August 8th. They issued an “outperform” rating and a $11.00 price objective on the stock. Piper Sandler began coverage on Allogene Therapeutics in a report on Friday, May 31st. They issued an “overweight” rating and a $11.00 target price for the company. Truist Financial reiterated a “buy” rating and issued a $14.00 target price (down from $17.00) on shares of Allogene Therapeutics in a report on Friday, August 9th. Finally, Citigroup lifted their target price on Allogene Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Three analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $9.96.

Allogene Therapeutics Stock Up 3.8 %

NASDAQ ALLO opened at $2.72 on Friday. The company has a market cap of $568.78 million, a price-to-earnings ratio of -1.52 and a beta of 0.83. Allogene Therapeutics, Inc. has a 52 week low of $2.01 and a 52 week high of $5.78. The business has a 50 day moving average price of $2.67 and a 200-day moving average price of $2.97.

Allogene Therapeutics (NASDAQ:ALLO) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.03. Allogene Therapeutics had a negative return on equity of 50.24% and a negative net margin of 223,139.98%. On average, equities research analysts anticipate that Allogene Therapeutics, Inc. will post -1.38 earnings per share for the current year.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).